DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)

Information source: Dong-A University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: B-cell Lymphomas

Intervention: Oxaliplatin, Prednisolone (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Dong-A University Hospital

Official(s) and/or principal investigator(s):
Cheolwon Suh, M.D., Ph.D., Principal Investigator, Affiliation: Asan Medical Center
Sung Yong Oh, M.D., Ph.D., Study Director, Affiliation: Dong-A University

Summary

The investigators are willing to investigate the efficacy and safety of oxaliplatin and prednisolone (Ox-P) combination in patients with previously treated MZL who have a few clinical trial data.

Clinical Details

Official title: A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Response rate by International Working Group Response Criteria

Secondary outcome:

progression free survival

overall survival

Detailed description: Over its long survival duration, MZL often involves frequent relapses. Overall, more than 50% of MZL patients experience a relapse within 10 years. However, Relapsed or refractory MZL represent a therapeutic dilemma in every day clinical practice and no prospective studies on large series have been published so far. The rarity of these disorders and some difficulties in the differential diagnosis from other low-grade lymphoma subtypes are obstacles in conducting epidemiological surveys and in properly describing clinical features and outcomes. Oxaliplatin, a platinum coordination complex with an oxalato-ligand as the leaving group and a 1,2-diaminocyclohexane carrier, possesses higher cytotoxic potency on molar basis than cisplatin and carboplatin and was reported to be active in patients with NHL as a single agent. In addition, the substitution of cisplatin by oxaliplatin in the DHAP regimen, another commonly used one in relapsed or refractory NHL, showed meaningful antitumor activity with favourable toxicity profile. In the previous phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma, a total of 16 patients with MALT lymphoma of various sites of origin (four of the ocular adnexa, five of the salivary glands, three of the stomach, two of the lung, and one of the colon and the breast) were administered oxaliplatin at a dose of 130 mg/m2 infused during 2 hours every 3 weeks. Fifteen patients responded to chemotherapy, with nine achieving CR (56%), six (37. 5%) achieving partial response, and one achieving stable disease; the median time to response was 4 months (range; 2 to 4 months). Based upon the promising results of oxaliplatin regimen in refractory NHL and first-line treatment of MZL, The investigators are willing to investigate the efficacy and safety of oxaliplatin and prednisolone (Ox-P) combination in patients with previously treated MZL who have a few clinical trial data.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Histologically confirmed marginal zone B-cell lymphomas

- Failure to achieve a clinical benefit (≥SD) with the initial treatment, or recurrent

disease

- Performance status (ECOG) ≤2

- Age ≥ 20

- At least one or more bi-dimensionally measurable lesion(s) defined as; ≥2 cm by

conventional CT or ≥ 1 cm by spiral CT or skin lesion (photographs should be taken) or measurable lesion by physical examination

- Adequate kidney functions defined as; Cr < 2. 0 mg% or Ccr > 60 ml/min

- Adequate liver functions defined as; Transaminases < 3 X upper normal values;

Bilirubin < 2 mg%

- Adequate bone marrow functions defined as; ANC > 1500/㎕, platelet > 75000/㎕

- Ann Arbor stage III or IV

- Ann Arbor stage I or II, which is not adequate for RT or surgical approach (e. g.

multiple lung lesions, multiple colon involvement, remote abdominal LN with stomach involvement)

- Written informed consent approved by Institutional review board or Ethic committee

Exclusion Criteria:

- Any other malignancies within the past 5 years except skin basal cell ca or CIS of

cervix

- Serious co-morbid diseases

- Pregnancy or breast feeding

- Previous history of drug allergy to one of the drugs in the study regimen

- During this study duration, patients who take other clinical trial medication,

chemotherapy, hormonal therapy, or immunotherapy

Locations and Contacts

Dong-A University Hospital, Busan 602-715, Korea, Republic of
Additional Information

Starting date: October 2009
Last updated: November 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017